Phytic acid-based nanomedicine shows promise for metabolic dysfunction-associated steatohepatitis therapy

CePA exerts a liver-targeted mTOR repressive function, alleviating MASH progression and fat accumulation in high-fat diet-fed mice. Credit: Fenghua Xu, Shoujie Zhao, Yejing Zhu, Jun Zhu, Lingyang Kong, Huichen Li, Shouzheng Ma, Bo Wang, Yongquan Qu, Zhimin Tian, Junlong Zhao, Lei Liu Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses. Although the incidence of MASH is gradually increasing, there is a lack of effective drugs and methods for its treatment, thus limiting therapeutic options for MASH. Professor Liu Lei’s team has long focused on the treatment Read More